Appendix 1.

Cox regression models for associations of HCT-CI scores with risks of non-relapse (NRM) and overall mortality among recipients of autologous HCT and within subgroups of lymphoma versus multiple myeloma.

		NRM			Overall mortality
	HCT-CI scores	n	HR (95% CI)	P	n	HR (95% CI)	P
Lymphoma subgroup	* overall			0.043			0.001
	0	1243	1.00		1264	1.00
	0, but other comorbidity reported	311	0.96 (0.57–1.61)	0.863	318	0.99 (0.77–1.28)	0.959
	1–2	977	1.24 (0.88–1.73)	0.218	988	1.23 (1.05–1.46)	0.013
	3+	832	1.56 (1.12–2.17)	0.009	838	1.37 (1.15–1.62)	<0.0001
Myeloma subgroup	* overall			0.048			<0.0001
	0	1657	1.00		1949	1.00
	0, but other comorbidity reported	586	0.95 (0.59–1.55)	0.844	682	0.76 (0.59–0.98)	0.032
	1–2	1382	1.32 (0.93–1.87)	0.119	1620	1.39 (1.18–1.64)	<0.0001
	3+	1168	1.55 (1.09–2.20)	0.015	1386	1.43 (1.21–1.69)	<0.0001

^*The Cox regression models were adjusted for diagnosis category, chemo-sensitivity for lymphoma, stem cell source, KPS percentage, conditioning regimen, recipient age, recipient race, and interval between diagnosis and HCT.